|
Gene: HSPA12A |
Gene summary for HSPA12A |
Gene summary. |
Gene information | Species | Human | Gene symbol | HSPA12A | Gene ID | 259217 |
Gene name | heat shock protein family A (Hsp70) member 12A | |
Gene Alias | HSPA12A | |
Cytomap | 10q25.3 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A1B0GTF3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
259217 | HSPA12A | HCC1_Meng | Human | Liver | HCC | 8.94e-05 | -1.31e-02 | 0.0246 |
259217 | HSPA12A | Pt13.b | Human | Liver | HCC | 2.32e-02 | 1.00e-01 | 0.0251 |
259217 | HSPA12A | S014 | Human | Liver | HCC | 1.62e-24 | 7.87e-01 | 0.2254 |
259217 | HSPA12A | S015 | Human | Liver | HCC | 8.31e-25 | 8.92e-01 | 0.2375 |
259217 | HSPA12A | S016 | Human | Liver | HCC | 2.06e-34 | 9.16e-01 | 0.2243 |
259217 | HSPA12A | S028 | Human | Liver | HCC | 1.12e-07 | 3.29e-01 | 0.2503 |
259217 | HSPA12A | S029 | Human | Liver | HCC | 1.93e-06 | 3.25e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HSPA12A | SNV | Missense_Mutation | c.430N>T | p.Pro144Ser | p.P144S | protein_coding | tolerated(0.1) | benign(0.077) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
HSPA12A | SNV | Missense_Mutation | rs555217651 | c.1925N>A | p.Arg642His | p.R642H | protein_coding | tolerated(0.63) | probably_damaging(0.919) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
HSPA12A | SNV | Missense_Mutation | c.1181N>T | p.Ala394Val | p.A394V | protein_coding | tolerated(0.1) | probably_damaging(0.999) | TCGA-BH-A0WA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
HSPA12A | SNV | Missense_Mutation | rs199760082 | c.1420G>A | p.Asp474Asn | p.D474N | protein_coding | tolerated(0.17) | probably_damaging(0.991) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
HSPA12A | SNV | Missense_Mutation | novel | c.187G>A | p.Asp63Asn | p.D63N | protein_coding | tolerated_low_confidence(0.11) | benign(0.003) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
HSPA12A | SNV | Missense_Mutation | novel | c.474N>A | p.Met158Ile | p.M158I | protein_coding | deleterious(0.02) | probably_damaging(0.921) | TCGA-EW-A3U0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
HSPA12A | SNV | Missense_Mutation | novel | c.1357N>A | p.Ser453Thr | p.S453T | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
HSPA12A | insertion | Frame_Shift_Ins | novel | c.1524_1525insTCCAAACACACTGAACGCACGTGGACCGC | p.Gln509SerfsTer58 | p.Q509Sfs*58 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |||
HSPA12A | insertion | Nonsense_Mutation | novel | c.825_826insTAAGGG | p.Ser275_Ser276insTer | p.S275_S276ins* | protein_coding | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |||
HSPA12A | insertion | Frame_Shift_Ins | novel | c.824_825insGT | p.Ser275ArgfsTer16 | p.S275Rfs*16 | protein_coding | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |